Subject(s)
Clinical Laboratory Services/organization & administration , Internship and Residency/organization & administration , Intersectoral Collaboration , Laboratories, Hospital/organization & administration , Allergy and Immunology/education , Allergy and Immunology/organization & administration , Chemistry, Clinical/education , Chemistry, Clinical/organization & administration , Genetics/education , Genetics/organization & administration , Humans , Microbiology/education , Microbiology/organization & administration , Pathology, Clinical/education , Pathology, Clinical/organization & administrationSubject(s)
Chemistry, Clinical , Clinical Laboratory Techniques/trends , Congresses as Topic , Chemistry, Clinical/organization & administration , Chemistry, Clinical/standards , Chemistry, Clinical/trends , Clinical Laboratory Techniques/standards , Congresses as Topic/organization & administration , Congresses as Topic/standards , Congresses as Topic/trends , Europe , Humans , Societies, Scientific/organization & administration , Societies, Scientific/standards , Societies, Scientific/trends , SpainSubject(s)
Chemistry, Clinical , Clinical Laboratory Techniques/trends , Advisory Committees/organization & administration , Advisory Committees/standards , Chemistry, Clinical/organization & administration , Chemistry, Clinical/standards , Chemistry, Clinical/trends , Clinical Laboratory Techniques/methods , Congresses as Topic , Editorial Policies , Europe , France , Humans , Laboratories/organization & administration , Laboratories/standards , Laboratories/trends , Publishing/organization & administration , Publishing/standards , Publishing/trends , Societies, Scientific/organization & administration , Societies, Scientific/standards , SpainSubject(s)
Chemistry, Clinical , Clinical Laboratory Techniques , Internship and Residency , Chemistry, Clinical/education , Chemistry, Clinical/organization & administration , Chemistry, Clinical/trends , Clinical Laboratory Techniques/methods , Clinical Laboratory Techniques/standards , Congresses as Topic/organization & administration , Congresses as Topic/standards , Congresses as Topic/trends , Europe , Humans , Internship and Residency/organization & administration , Internship and Residency/standards , Laboratories/organization & administration , Laboratories/standards , Laboratories/trends , Societies, Medical/organization & administration , Societies, Medical/standards , Societies, Medical/trends , Spain , Students, MedicalABSTRACT
This document provides a joint recommendation for venous blood sampling of the European federation of clinical chemistry and laboratory medicine (EFLM) Working Group for preanalytical phase (WG-PRE) and Latin American working group for preanalytical phase (WG-PRE-LATAM) of the Latin America confederation of clinical biochemistry (COLABIOCLI). It offers guidance on the requirements for ensuring that blood collection is a safe and patient-centered procedure and provides practical guidance on how to successfully overcome potential barriers and obstacles to its widespread implementation. The target audience for this recommendation are healthcare staff members directly involved in blood collection. This recommendation applies to the use of a closed blood collection system and does not provide guidance for the blood collection with an open needle and syringe and catheter collections. Moreover, this document neither addresses patient consent, test ordering, sample handling and transport nor collection from children and unconscious patients. The recommended procedure is based on the best available evidence. Each step was graded using a system that scores the quality of the evidence and the strength of the recommendation. The process of grading was done at several face-to-face meetings involving the same mixture of stakeholders stated previously. The main parts of this recommendation are: 1) Pre-sampling procedures, 2) Sampling procedure, 3) Post-sampling procedures and 4) Implementation. A first draft of the recommendation was circulated to EFLM members for public consultation. WG-PRE-LATAM was also invited to comment the document. A revised version has been sent for voting on to all EFLM and COLABIOCLI members and has been officially endorsed by 33/40 EFLM and 21/21 COLABIOCLI members. We encourage professionals throughout Europe and Latin America to adopt and implement this recommendation to improve the quality of blood collection practices and increase patient and workers safety.
Subject(s)
Blood Specimen Collection/standards , Chemistry, Clinical/standards , Clinical Laboratory Techniques/standards , Phlebotomy/standards , Pre-Analytical Phase/standards , Adult , Blood Specimen Collection/methods , Chemistry, Clinical/organization & administration , Child , Clinical Laboratory Techniques/methods , Europe , Humans , Latin America , Phlebotomy/methods , Pre-Analytical Phase/methods , Societies, Medical/organization & administration , Societies, Medical/standards , Specimen Handling/methods , Specimen Handling/standardsABSTRACT
Toxicological screening is a specific approach to analytical toxicology that uses analytical tools such as GC-MS, LC-UV (diode array) or LC-MS. Toxicological screening allows the detection and simultaneous identification of a large number of compounds. The results may be based on the use of one or more techniques. As part of the accreditation process for medical biology examinations according to standard NF EN ISO 15189, the group from SFTA and SFBC recommends an approach to accredit toxicological screening. Indeed, the complexity of the accreditation of this analysis comes in particular from the high number of compounds that can be detected. Validation parameters are discussed in the specific context of toxicological screening by considering two distinct approaches: the simple identification of compounds, or the identification and estimation of a range of concentration related to clinical outcomes.
Subject(s)
Accreditation , Chemistry, Clinical/standards , Diagnostic Tests, Routine/standards , Toxicology/standards , Chemistry, Clinical/methods , Chemistry, Clinical/organization & administration , Chromatography, Liquid , Diagnostic Tests, Routine/methods , Equipment Contamination , Gas Chromatography-Mass Spectrometry , High-Throughput Screening Assays/methods , High-Throughput Screening Assays/standards , Humans , Mass Screening/methods , Mass Screening/standards , Quality Control , Societies, Medical/organization & administration , Societies, Medical/standards , Tandem Mass Spectrometry , Toxicology/methods , Toxicology/organization & administration , Validation Studies as TopicABSTRACT
Analytical performance specifications are crucial in test development and quality control. Although consensus has been reached on the use of biological variation to derive these specifications, no consensus has been reached which model should be preferred. The Six Sigma concept is widely applied in industry for quality specifications of products and can well be compared with Six Sigma models in clinical chemistry. However, the models for measurement specifications differ considerably between both fields: where the sigma metric is used in clinical chemistry, in industry the Number of Distinct Categories is used instead. In this study the models in both fields are compared and discussed.
Subject(s)
Chemistry, Clinical/organization & administration , Clinical Laboratory Techniques/standards , Industry/organization & administration , Total Quality Management , Chemistry, Clinical/standards , Industry/standards , Models, Organizational , Quality Control , Reproducibility of ResultsABSTRACT
Introducción. Con el objetivo de asegurar la confiabilidad de sus resultados, los laboratorios de análisis clínicos deben implementar un programa de control de calidad interno suficientemente bueno para alcanzar metas analíticas con los mayores estándares posibles. Materiales y métodos. Se realizó un estudio retrospectivo, descriptivo y longitudinal. Para este estudio se emplearon los resultados del control de calidad interno del área de Química Clínica de un laboratorio mexicano obtenidos en el periodo comprendido entre julio y diciembre del 2016. Resultados. Para el 100% de los analitos en estudio se alcanzaron las metas de error total máximo permitido establecidas por el Clinical Laboratory Improvement Amendments. En cuanto a las metas basadas en variabilidad biológica, se demostró el alcance de metas deseables u óptimas en 89% de los analitos estudiados, obteniéndose resultados inferiores en aquellos analitos con bajo índice de variabilidad biológica. Finalmente, en cuanto a los resultados de la sigmametría, los resultados son muy variados dependiendo de las metas analíticas utilizadas, obteniéndose los valores sigma más bajos en cuanto menor es la variabilidad biológica del analito estudiado. Conclusiones. Sobre la base de nuestros resultados podemos indicar que un modelo de control de calidad adecuado en Química Clínica pudiera incluir inicialmente el establecimiento de metas analíticas utilizando el modelo de CLIA para aquellos analitos con baja variabilidad biológica y el modelo de variabilidad biológica en metas deseables para el resto de los analitos. Con los instrumentos utilizados en este estudio, es factible alcanzar dichas metas (AU)
Introduction. With the aim of providing clinically relevant results, the clinical laboratory must implement a sufficiently good internal quality control system in order to achieve analytical goals with the highest possible standards. Materials and methods. A retrospective, descriptive, and longitudinal study was performed in order to study the internal quality control results of the Clinical Chemistry area of a Mexican laboratory obtained during the period from July to December 2016. Results. The Clinical Laboratory Improvement Amendments (CLIA) goals of maximum total allowable error were achieved in 100% of the analytes studied. In the case of biological variation goals, desirable or optimal goals were achieved for in 89% of the analytes studied, with inferior results being obtained in these analytes with a low biological variability index. Finally, as regards the results of sigma values, our results varied considerably depending on the analytical specifications used, achieving the lowest values in those analytes with the lowest biological variability index. Conclusions. Based on our results we can suggest that an adequate quality control model in Clinical Chemistry could initially include the establishment of analytical specifications based on CLIA for those analytes with low biological variation, and the desirable goals of biological variation for the rest of the analytes. Both goals can be achieved by the instruments used in this study (AU)
Subject(s)
Humans , Clinical Laboratory Services/organization & administration , Chemistry, Clinical/organization & administration , Quality Control , Clinical Laboratory Techniques/standards , Laboratory Proficiency Testing , Retrospective StudiesABSTRACT
Background Turnaround time can be defined as the time from receipt of a sample by the laboratory to the validation of the result. The Royal College of Pathologists recommends that a number of performance indicators for turnaround time should be agreed with stakeholders. The difficulty is in arriving at a goal which has some evidence base to support it other than what may simply be currently achievable technically. This survey sought to establish a professional consensus on the goals and meaning of targets for laboratory turnaround time. Methods A questionnaire was circulated by the National Audit Committee to 173 lead consultants for biochemistry in the UK. The survey asked each participant to state their current target turnaround time for core investigations in a broad group of clinical settings. Each participant was also asked to provide a professional opinion on what turnaround time would pose an unacceptable risk to patient safety for each departmental category. A super majority (2/3) was selected as the threshold for consensus. Results The overall response rate was 58% ( n = 100) with a range of 49-72% across the individual Association for Clinical Biochemistry and Laboratory Medicine regions. The consensus optimal turnaround time for the emergency department was <1 h with >2 h considered unacceptable. The times for general practice and outpatient department were <24 h and >48 h and for Wards <4 h and >12 h, respectively. Conclusions We consider that the figures provide a useful benchmark of current opinion, but clearly more empirical standards will have to develop alongside other aspects of healthcare delivery.
Subject(s)
Chemistry, Clinical/organization & administration , Delivery of Health Care/statistics & numerical data , Emergency Service, Hospital/organization & administration , Research Design/statistics & numerical data , Benchmarking , Chemistry, Clinical/methods , Clinical Chemistry Tests , Humans , Laboratories , Quality Assurance, Health Care , Surveys and Questionnaires , Time Factors , United KingdomABSTRACT
Patient safety is a leading challenge in healthcare and from the laboratory perspective it is now well established that preanalytical errors are the major contributor to the overall rate of diagnostic and therapeutic errors. To address this, the European Federation of Clinical Chemistry and Laboratory Medicine Working Group for Preanalytical Phase (EFLM WG-PRE) was established to lead in standardization and harmonization of preanalytical policies and practices at a European level. One of the key activities of the WG-PRE is the organization of the biennial EFLM-BD conference on the preanalytical phase to provide a forum for National Societies (NS) to discuss their issues. Since 2012, a year after the first Preanalytical phase conference, there has been a rapid growth in the number of NS with a working group engaged in preanalytical phase activities and there are now at least 19 countries that have one. As a result of discussions with NS at the third conference held in March 2015 five key areas were identified as requiring harmonisation. These were test ordering, sample transport and storage, patient preparation, sampling procedures and management of unsuitable specimens. The article below summarises the work that has and will be done in these areas. The goal of this initiative is to ensure the EFLM WG-PRE produces work that meets the needs of the European laboratory medicine community. Progress made in the identified areas will be updated at the next preanalytical phase conference and show that we have produced guidance that has enhanced standardisation in the preanalytical phase and improved patient safety throughout Europe.
Subject(s)
Blood Chemical Analysis/standards , Chemistry, Clinical/standards , Chemistry, Clinical/organization & administration , Europe , Humans , Practice Guidelines as Topic , Reference Standards , Societies, MedicalABSTRACT
BACKGROUND: Prospective risk analysis (PRA) is an essential element in quality assurance for clinical laboratories. Practical approaches to conducting PRA in laboratories, however, are scarce. METHODS: On the basis of the classical Failure Mode and Effect Analysis method, an approach to PRA was developed for application to key laboratory processes. First, the separate, major steps of the process under investigation are identified. Scores are then given for the Probability (P) and Consequence (C) of predefined types of failures and the chances of Detecting (D) these failures. Based on the P and C scores (on a 10-point scale), an overall Risk score (R) is calculated. The scores for each process were recorded in a matrix table. Based on predetermined criteria for R and D, it was determined whether a more detailed analysis was required for potential failures and, ultimately, where risk-reducing measures were necessary, if any. RESULTS: As an illustration, this paper presents the results of the application of PRA to our pre-analytical and analytical activities. The highest R scores were obtained in the stat processes, the most common failure type in the collective process steps was 'delayed processing or analysis', the failure type with the highest mean R score was 'inappropriate analysis' and the failure type most frequently rated as suboptimal was 'identification error'. CONCLUSIONS: The PRA designed is a useful semi-objective tool to identify process steps with potential failures rated as risky. Its systematic design and convenient output in matrix tables makes it easy to perform, practical and transparent.
Subject(s)
Laboratories/organization & administration , Quality Control , Risk Assessment/methods , Chemistry, Clinical/organization & administration , Chemistry, Clinical/standards , Laboratories/statistics & numerical data , Medical Errors , Netherlands , Risk ManagementABSTRACT
Verification of new lot reagent's suitability is necessary to ensure that results for patients' samples are consistent before and after reagent lot changes. A typical procedure is to measure results of some patients' samples along with quality control (QC) materials. In this study, the results of patients' samples and QC materials in reagent lot changes were analysed. In addition, the opinion regarding QC target range adjustment along with reagent lot changes was proposed. Patients' sample and QC material results of 360 reagent lot change events involving 61 analytes and eight instrument platforms were analysed. The between-lot differences for the patients' samples (ΔP) and the QC materials (ΔQC) were tested by Mann-Whitney U tests. The size of the between-lot differences in the QC data was calculated as multiples of standard deviation (SD). The ΔP and ΔQC values only differed significantly in 7.8% of the reagent lot change events. This frequency was not affected by the assay principle or the QC material source. One SD was proposed for the cutoff for maintaining pre-existing target range after reagent lot change. While non-commutable QC material results were infrequent in the present study, our data confirmed that QC materials have limited usefulness when assessing new reagent lots. Also a 1 SD standard for establishing a new QC target range after reagent lot change event was proposed.
Subject(s)
Chemistry, Clinical/methods , Chemistry, Clinical/standards , Indicators and Reagents , Quality Control , Reagent Kits, Diagnostic , Chemistry, Clinical/organization & administration , Clinical Chemistry Tests/standards , Data Interpretation, Statistical , Humans , LaboratoriesABSTRACT
BACKGROUND: European questionnaire survey was conducted by the European Federation of Clinical Chemistry and Laboratory Medicine Working Group for the Preanalytical Phase (EFLM WG-PA) to assess how phlebotomy is performed in EFLM countries, including differences in personnel, level of education and skills, and to investigate the presence and compliance of national phlebotomy guidelines on this matter. METHODS: A questionnaire was constructed containing questions elucidating different aspects of the organization behind the phlebotomy praxis on a national basis, including questions on the staff performing phlebotomy, the education of these staff members, and the existence of and adherence to national guidelines. All 39 EFLM member countries were invited to participate. RESULTS: In total 28/39 (72%) EFLM member countries responded. Seven out of the 28 (25%) have national phlebotomy guidelines and five have implemented other guidelines. The estimated compliance with phlebotomy guidance for the laboratories in the countries that have national guidelines available is poor, regardless to whether the phlebotomy was under the laboratory control or not. Most countries were interested in EFLM guidelines and to participate in a pilot EFLM preanalytical phase external quality assessment (EQA) scheme. In the responding EFLM member countries, the majority of phlebotomy is performed by nurses and laboratory technicians. Their basic education is generally 4-5 years of high school, followed by 2-5 years of colleague or university studies. Only a third (10/28; 36%) of the participating member countries has any specific training available as a continuous educational resource. A specific training for phlebotomy is not part of the education required to become qualified in 6/28 (21%) and 9/28 (32%) of countries for nurses and laboratory technicians, respectively. In countries and professions where training is required, most require more than 5 h of training. CONCLUSIONS: Based on the results of this survey we conclude the following: 1) There is a need to assess the quality of current practices, compliance to the CLSI H3-A6 guidelines and to identify some most critical steps which occur during phlebotomy, in different healthcare settings, across Europe; 2) Existing CLSI H3-A6 phlebotomy guidelines should be adapted and used locally in all European countries which do not have their own guidelines; 3) National EFLM societies need to be engaged in basic training program development and continuous education of healthcare phlebotomy staff (implementing the certification of competence).
Subject(s)
Chemistry, Clinical/education , Chemistry, Clinical/standards , Guidelines as Topic , Medical Laboratory Science/education , Medical Laboratory Science/standards , Phlebotomy , Chemistry, Clinical/organization & administration , Data Collection , Educational Status , European Union , Humans , Medical Laboratory Science/organization & administration , Professional Practice , Surveys and QuestionnairesSubject(s)
Automation, Laboratory/history , Biochemistry/history , Chemistry, Clinical/history , Automation, Laboratory/instrumentation , Automation, Laboratory/methods , Biochemistry/organization & administration , Chemistry, Clinical/organization & administration , History, 20th Century , Humans , United KingdomABSTRACT
Laboratory medicine is at the heart of modern health care and diagnosis and effective treatment of patients is impossible without high-quality bioanalytical services. The European Federation of Clinical Chemistry and Laboratory Medicine is a professional federation working to ensure high standards across the discipline in all European countries. This article describes our work in science, education and professional development.
Subject(s)
Chemistry, Clinical/standards , Clinical Laboratory Techniques/standards , Chemistry, Clinical/organization & administration , Europe , HumansABSTRACT
To meet the increased clinical demands of our hospital expansion, improve quality, and reduce costs, our tertiary care, pediatric core laboratory used the Toyota Production System lean processing to reorganize our 24-hour, 7 d/wk core laboratory. A 4-month, consultant-driven process removed waste, led to a physical reset of the space to match the work flow, and developed a work cell for our random access analyzers. In addition, visual controls, single piece flow, standard work, and "5S" were instituted. The new design met our goals as reflected by achieving and maintaining improved turnaround time (TAT; mean for creatinine reduced from 54 to 23 minutes) with increased testing volume (20%), monetary savings (4 full-time equivalents), decreased variability in TAT, and better space utilization (25% gain). The project had the unanticipated consequence of eliminating STAT testing because our in-laboratory TAT for routine testing was less than our prior STAT turnaround goal. The viability of this approach is demonstrated by sustained gains and further PDCA (Plan, Do, Check, Act) improvements during the 4 years after completion of the project.
Subject(s)
Chemistry, Clinical/organization & administration , Efficiency, Organizational , Laboratories, Hospital/organization & administration , Pediatrics/organization & administration , Quality Assurance, Health Care , Chemistry, Clinical/standards , Child , Hospitals, University , Humans , Laboratories, Hospital/standards , Pediatrics/standards , Process Assessment, Health Care , Time FactorsABSTRACT
The mission of translational research involves difficult tasks to be accomplished for its ultimate goal, i.e., the introduction of novel, effective therapeutic strategies in the clinic to diminish human suffering and cure life-threatening diseases. Translational research (also referred to as translational medicine) facilitates the translation of investment in biomedical research into successful medical treatment. This includes the transfer of diagnostic and therapeutic advances by proving their efficacy in large evidence-based trials. Through the study of humans novel insights about disease are brought back to the laboratory to identify new, observation-based strategies. This "two-way road" ("bench to bedside and bedside to bench") process includes formulating guidelines for drug development and principles for new therapeutic strategies; initiating clinical investigations that provide the biological basis for new therapies, and related clinical trials; defining therapeutic targets and clinical endpoints. It requires a systematic approach beginning with specimen sampling, patient data collection, laboratory investigations, data analysis, preclinical testing, clinical trials, treatment efficacy monitoring, and finally the evaluation of therapeutic result. The marathon well symbolizes the enormous efforts undertaken by clinicians, scientists, regulators, ethicists, patient advocates, drug developers, and others, coordinately attempting to overcome obstacles along this road toward the final "marathon goal in medicine".